BIOMAT Database Logo BIOMAT Database Logo

Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. 1997

R D Alvarez, and E E Partridge, and M B Khazaeli, and G Plott, and M Austin, and L Kilgore, and C D Russell, and T Liu, and W E Grizzle, and J Schlom, and A F LoBuglio, and R F Meredith
Department of Obstetrics and Gynecology, University of Alabama at Birmingham, USA.

BACKGROUND Twenty-seven ovarian cancer patients who failed chemotherapy entered a phase I/II trial of intraperitoneal 177Lu-CC49 antibody. METHODS Patients had disease confined to the abdominal cavity +/- retroperitoneal lymph nodes, adequate organ function, and no previous radiation. RESULTS The most common side effects were delayed, transient arthralgia (10/27) and marrow suppression with 1.665 GBq/m2 (45 mCi/m2), which was considered the maximum tolerated dose. One of thirteen patients with gross disease had >50% tumor reduction after therapy, whereas most others with gross disease progressed (one went off study with stable disease at 11 weeks). Seven of nine patients with <1-cm nodules progressed in < or =21 months, and two of nine remain without evidence of disease at 4 to 5 months. Of patients with microscopic or occult disease, one relapsed at 10 months and four of five remain without evidence of disease at >6 to 35 months. CONCLUSIONS Marrow suppression was the dose-limiting toxic effect of intraperitoneal immunotherapy with 177Lu-CC49. Antitumor effects were noted against chemotherapy-resistant ovarian cancer, even at lower dose levels, and resulted in prolonged disease-free survival of most patients with microscopic disease. This form of treatment deserves further study.

UI MeSH Term Description Entries
D007274 Injections, Intraperitoneal Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall. Intraperitoneal Injections,Injection, Intraperitoneal,Intraperitoneal Injection
D008187 Lutetium An element of the rare earth family of metals. It has the atomic symbol Lu, atomic number 71, and atomic weight 175.
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010976 Platelet Count The number of PLATELETS per unit volume in a sample of venous BLOOD. Blood Platelet Count,Blood Platelet Number,Platelet Number,Blood Platelet Counts,Blood Platelet Numbers,Count, Blood Platelet,Count, Platelet,Counts, Blood Platelet,Counts, Platelet,Number, Blood Platelet,Number, Platelet,Numbers, Blood Platelet,Numbers, Platelet,Platelet Count, Blood,Platelet Counts,Platelet Counts, Blood,Platelet Number, Blood,Platelet Numbers,Platelet Numbers, Blood
D011868 Radioisotopes Isotopes that exhibit radioactivity and undergo radioactive decay. (From Grant & Hackh's Chemical Dictionary, 5th ed & McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Daughter Isotope,Daughter Nuclide,Radioactive Isotope,Radioactive Isotopes,Radiogenic Isotope,Radioisotope,Radionuclide,Radionuclides,Daughter Nuclides,Daugter Isotopes,Radiogenic Isotopes,Isotope, Daughter,Isotope, Radioactive,Isotope, Radiogenic,Isotopes, Daugter,Isotopes, Radioactive,Isotopes, Radiogenic,Nuclide, Daughter,Nuclides, Daughter
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D004307 Dose-Response Relationship, Radiation The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation. Dose Response Relationship, Radiation,Dose-Response Relationships, Radiation,Radiation Dose-Response Relationship,Radiation Dose-Response Relationships,Relationship, Radiation Dose-Response,Relationships, Radiation Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R D Alvarez, and E E Partridge, and M B Khazaeli, and G Plott, and M Austin, and L Kilgore, and C D Russell, and T Liu, and W E Grizzle, and J Schlom, and A F LoBuglio, and R F Meredith
Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer.
February 1994, Cancer,
R D Alvarez, and E E Partridge, and M B Khazaeli, and G Plott, and M Austin, and L Kilgore, and C D Russell, and T Liu, and W E Grizzle, and J Schlom, and A F LoBuglio, and R F Meredith
Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
November 2005, Clinical cancer research : an official journal of the American Association for Cancer Research,
R D Alvarez, and E E Partridge, and M B Khazaeli, and G Plott, and M Austin, and L Kilgore, and C D Russell, and T Liu, and W E Grizzle, and J Schlom, and A F LoBuglio, and R F Meredith
Phase I/II study of intraperitoneal mitoxantrone in refractory ovarian cancer.
April 1994, Annals of oncology : official journal of the European Society for Medical Oncology,
R D Alvarez, and E E Partridge, and M B Khazaeli, and G Plott, and M Austin, and L Kilgore, and C D Russell, and T Liu, and W E Grizzle, and J Schlom, and A F LoBuglio, and R F Meredith
Intraperitoneal radioimmunotherapy for ovarian cancer.
May 1989, British journal of obstetrics and gynaecology,
R D Alvarez, and E E Partridge, and M B Khazaeli, and G Plott, and M Austin, and L Kilgore, and C D Russell, and T Liu, and W E Grizzle, and J Schlom, and A F LoBuglio, and R F Meredith
Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
April 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine,
R D Alvarez, and E E Partridge, and M B Khazaeli, and G Plott, and M Austin, and L Kilgore, and C D Russell, and T Liu, and W E Grizzle, and J Schlom, and A F LoBuglio, and R F Meredith
Phase I-II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer.
January 1993, European journal of cancer (Oxford, England : 1990),
R D Alvarez, and E E Partridge, and M B Khazaeli, and G Plott, and M Austin, and L Kilgore, and C D Russell, and T Liu, and W E Grizzle, and J Schlom, and A F LoBuglio, and R F Meredith
Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu.
December 2011, Bioconjugate chemistry,
R D Alvarez, and E E Partridge, and M B Khazaeli, and G Plott, and M Austin, and L Kilgore, and C D Russell, and T Liu, and W E Grizzle, and J Schlom, and A F LoBuglio, and R F Meredith
Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.
May 2004, Clinical cancer research : an official journal of the American Association for Cancer Research,
R D Alvarez, and E E Partridge, and M B Khazaeli, and G Plott, and M Austin, and L Kilgore, and C D Russell, and T Liu, and W E Grizzle, and J Schlom, and A F LoBuglio, and R F Meredith
A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancer.
January 1992, European journal of cancer (Oxford, England : 1990),
R D Alvarez, and E E Partridge, and M B Khazaeli, and G Plott, and M Austin, and L Kilgore, and C D Russell, and T Liu, and W E Grizzle, and J Schlom, and A F LoBuglio, and R F Meredith
Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
October 2005, Cancer biotherapy & radiopharmaceuticals,
Copied contents to your clipboard!